Inflammatory signaling
In immune-cell experiments, 10 nM KPV reduced TNF-α-driven activation across NF-κB and MAPK signaling.
Coming soonKPV · preclinical research
Three amino acids. Measured inflammatory endpoints.
Cell experiments measured lower NF-κB and MAPK activation. In mouse colitis research, orally administered KPV reduced colonic inflammation. Human injectable KPV studies have not been identified.
Be first to know when orders open.
Product updates and occasional emails. Unsubscribe anytime.
3amino acids
10 mgplanned vial
Closedordering status
The short peptide
Three amino acids. Two inflammatory pathways.
Lysine. Proline. Valine. KPV is the C-terminal fragment of α-MSH. PepT1 carries tripeptides across the intestinal cell membrane. After KPV entered the cells, experiments measured lower NF-κB and MAPK signaling.
KPV 10 mgComing soon
A prescription vial with a U.S. pharmacy behind it.
If KPV launches, it will be dispensed by a licensed U.S. compounding pharmacy. The patient-specific label will identify the formulation, strength, storage instructions, and beyond-use date.
- Active
- KPV
- Strength
- 10 mg
- Package
- 5 mL vial
- Planned supply
- 20 days
- Status
- Orders closed
What researchers measured
Cell and mouse studies measured inflammatory endpoints.
The published KPV record is preclinical. Here is what the cell and mouse experiments directly measured.
Intestinal inflammation
Two independent 2008 studies found less colonic inflammation and earlier recovery in mouse models of colitis.
Barrier transport
Cell work identified PepT1 as a transporter that carries KPV into intestinal epithelial and immune cells.
The transport step
PepT1The intestinal cell has a door for tripeptides.
In Caco-2 intestinal cells and Jurkat immune cells, researchers identified PepT1-mediated KPV uptake. Blocking PepT1 blocked the anti-inflammatory response in the experiment.
Inside the cell
One tripeptide. Two signal networks measured lower.
With TNF-α driving inflammation, 10 nM KPV reduced NF-κB and MAPK pathway activation in cell experiments.
10 nMKPV in the cell experiment
NF-κBinflammatory transcription pathway
MAPKcellular stress-signaling pathway
The animal evidence
Both colitis models measured less inflammation.
In DSS colitis and CD45RB-high transfer colitis, KPV-treated mice recovered weight earlier and had less inflammatory damage in colon tissue. A separate oral KPV experiment used five mice per group and measured lower colonic MPO activity alongside histology.
2murine colitis models
5mice per group in one DSS experiment
3endpoint types: weight, MPO, histology
Why Rebody
Know what is in the vial and who filled it.
Licensed U.S. pharmacy
If offered, each prescription would be filled through a licensed compounding pharmacy.
Patient-specific label
The formulation, strength, storage instructions, and beyond-use date would appear on the dispensed vial.
Prescription required
Ordering would begin with Rebody intake and a prescription decision—not a research-marketplace checkout.
What has been studied
Cell and mouse findings. No human KPV results yet.
Published KPV evidence comes from cell experiments and animal models. No human exposure, pharmacokinetic, safety, or efficacy studies were identified for KPV by any route. The proposed Rebody format is an injection; the published studies do not establish results for that finished format.
Read the evidence review ↗Availability
KPV orders are closed.
Join the list for the final formulation, directions, price, pharmacy, supply, states served, and opening date.
KPV questions
Clear answers before orders open.
Coming soon
Be first to know when KPV becomes available.
Get the final price, formulation, prescribed directions, states served, sourcing details, and order date.
Coming soonOrders currently closed
Get KPV launch updates.
Join the list for KPV pricing, formulation, directions, states served, sourcing, and availability.
Product updates and occasional emails. Unsubscribe anytime.